TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15864232

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy during index hospitalization
Number of subjects: 10288

Group type: COMPARATOR
Intervention: No lipid-lowering therapy during index hospitalization
Number of subjects: 10288

Group type: COMPARATOR
Intervention: Patients with prior history of hyperlipidemia not discharged on lipid-lowering therapy
Number of subjects: 10288

Group type: EXPERIMENTAL
Intervention: Inpatient lipid-lowering therapy
Number of subjects: 10288
Study: 14578647

Group type: EXPERIMENTAL
Intervention: Chemotherapy agents (e.g., fluorouracil, gemcitabine, taxanes, capecitabine)
Number of subjects: 0
Study: 11275925

Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab and reduced-dose thrombolytic agent) with adjunctive PCI
Number of subjects: 410

Group type: COMPARATOR
Intervention: Full-dose thrombolytic agent alone with adjunctive PCI
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Combination therapy (abciximab) with adjunctive PCI
Number of subjects: 410

Group type: COMPARATOR
Intervention: Combination therapy (abciximab) without adjunctive PCI
Number of subjects: 410

Group type: COMPARATOR
Intervention: Thrombolytic therapy alone with adjunctive PCI
Number of subjects: 410

Group type: COMPARATOR
Intervention: Thrombolytic therapy alone without adjunctive PCI
Number of subjects: 410
Study: 9249638

Group type: EXPERIMENTAL
Intervention: Polylactic-acid-based bioabsorbable barrier (test treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-absorbable ePTFE barrier (control treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safety data comparison
Number of subjects: 0
Study: 8272333

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2
Study: 3427802

Group type: EXPERIMENTAL
Intervention: Extracting (pulling) a tube from the tympanic membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excising (freshening) the edge of the defect at the time of removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29594999

Group type: EXPERIMENTAL
Intervention: D55 light source
Number of subjects: 49

Group type: COMPARATOR
Intervention: D65 light source
Number of subjects: 49
Study: 26916287

Group type: EXPERIMENTAL
Intervention: Chronic neck pain (NP) group
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Chronic widespread pain (CWP) group
Number of subjects: 77

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 77
Study: 26250474

Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; higher levels observed in blood samples taken 4 or more years before diagnosis.
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed 2 years after blood draw.
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed 3 years after blood draw.
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated for those diagnosed less than 2 years after blood draw.
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: LINE-1 DNA methylation levels; evaluated overall.
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Alu DNA methylation levels; evaluated overall.
Number of subjects: 1397
Study: 23887448

Group type: EXPERIMENTAL
Intervention: Nootropics and antioxidants (specifically phenotropil and mexidol)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Antioxidant mexidol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nootropics (general)
Number of subjects: 75
Study: 21070344

Group type: EXPERIMENTAL
Intervention: Programme-assessed treatment (elaborate feedback)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Student-assessed treatment (minimal feedback)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both CAIs
Number of subjects: 97
Study: 18439164

Group type: EXPERIMENTAL
Intervention: Paced ECGs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonpaced ECGs
Number of subjects: 30
Study: 16761129

Group type: COMPARATOR
Intervention: d-amphetamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: d,l-methamphetamine
Number of subjects: 60

Group type: COMPARATOR
Intervention: d-methamphetamine
Number of subjects: 60
Study: 14586363

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.1 mg, 0.2 mg, or 0.4 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 144
Study: 10880803

Group type: EXPERIMENTAL
Intervention: Laughter
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Startle reflex
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Audiospinal reflex
Number of subjects: 26
Study: 8937366

Group type: EXPERIMENTAL
Intervention: Penthienate (5 mg, three times a day for 4 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: COMPARATOR
Intervention: Propantheline (15 mg, three times a day for 4 weeks)
Number of subjects: 43
Study: 31750405

Group type: EXPERIMENTAL
Intervention: In-hospital care for malnourished children
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Outpatient care for malnourished children
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Comparison of recovery rates between HIV seropositive and seronegative children
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Quality of care (QoC) assessment
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Participatory approach to improve QoC
Number of subjects: 1428
Study: 29485533

Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment
Number of subjects: 104
Study: 26656776

Group type: EXPERIMENTAL
Intervention: Physical activity-based intervention targeting childcare providers, including two 3-hour workshops and a training manual, with booster sessions over 6 months.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Physical activity-based intervention targeting childcare providers.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group implementing standard curriculum.
Number of subjects: 83
Study: 24688087

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5) plus Pemetrexed (500 mg/m²)
Number of subjects: 20
Study: 22306290

Group type: EXPERIMENTAL
Intervention: Thoughts of support provision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thoughts of support receipt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-supportive social contact
Number of subjects: 0
Study: 18093716

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17145528

Group type: EXPERIMENTAL
Intervention: Intensity‐modulated radiotherapy (IMRT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 51
Study: 12584508

Group type: EXPERIMENTAL
Intervention: Cervical contralateral lateral glide mobilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 20
Study: 10632912

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microgram.kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam 0.4 mg.kg‐1
Number of subjects: 50
Study: 9574347

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 50
Study: 8311533

Group type: EXPERIMENTAL
Intervention: Treatment with steroids
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Laboratory parameters and temporal artery histology
Number of subjects: 74
Study: 2423803

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 44
Study: 29136115

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 326

Group type: COMPARATOR
Intervention: cART-naive comparator group
Number of subjects: 326
Study: 27098346

Group type: EXPERIMENTAL
Intervention: Exercise training intervention
Number of subjects: 119
Study: 24102912

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training (CON)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Interval aerobic exercise training (INT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 43
Study: 22341744

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 539
Study: 20538959

Group type: EXPERIMENTAL
Intervention: Numeric prognosis statement (10% chance of surviving)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Qualitative prognosis statement (very unlikely to survive)
Number of subjects: 169
Study: 18490790

Group type: EXPERIMENTAL
Intervention: team goal-setting
Number of subjects: 86

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 86
Study: 16942452

Group type: EXPERIMENTAL
Intervention: Mime therapy for three months (including massage, relaxation, inhibition of synkinesis, and coordination and emotional expression exercises)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mime therapy for three months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 50
Study: 12970808

Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 237

Group type: COMPARATOR
Intervention: Telephone triage
Number of subjects: 237
Study: 10735462

Group type: EXPERIMENTAL
Intervention: Dopamine 5 microg/kg per min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Volume expansion with albumin 20% 15 ml/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 36
Study: 9021321

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan, 1.5% sodium lauryl sulfate (SLS), and diluted propylene glycol (PG) in water (1:8) with 0.5% zinc citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan with 0.5% zinc citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (triclosan/ethanol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan in either propylene glycol (PG) or copolymer/PG
Number of subjects: 0
Study: 1392423

Group type: EXPERIMENTAL
Intervention: Intravenous ANF(99‐126) (bolus 100 micrograms/kg, 30‐min infusion of 0.1 micrograms/kg.min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined releasing hormone administration
Number of subjects: 10
Study: 3904233

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 2 years
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Untreated control group with systemic therapy reserved until the time of relapse
Number of subjects: 1285
Study: 29806520

Group type: EXPERIMENTAL
Intervention: Probiotics (Clostridium butyricum combined with Bifidobacterium infantis)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No probiotics
Number of subjects: 67
Study: 28800755

Group type: EXPERIMENTAL
Intervention: Basic exercises combined with verbal stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic exercises without verbal stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional exercise training with verbal stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Functional exercise training without verbal stimulation
Number of subjects: 0
Study: 26386792

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243

Group type: EXPERIMENTAL
Intervention: Prasugrel with PPI
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Clopidogrel with PPI
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Prasugrel vs Clopidogrel
Number of subjects: 7243
Study: 23959209

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (CT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (15 CHF patients)
Number of subjects: 45
Study: 20580193

Group type: EXPERIMENTAL
Intervention: Cementless double‐wedged tapered stem with alumina‐alumina bearing
Number of subjects: 848

Group type: COMPARATOR
Intervention: Polyethylene control group
Number of subjects: 848
Study: 18815508

Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study: 17167974

Group type: COMPARATOR
Intervention: Splenectomy without immunotherapy (OK-432 administration)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Splenectomy with immunotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spleen preservation without immunotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Spleen preservation with immunotherapy
Number of subjects: 45
Study: 12860257

Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine (250 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine (second injection)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CETi‐1 vaccine
Number of subjects: 36
Study: 11432180

Group type: EXPERIMENTAL
Intervention: Greater palatine nerve block
Number of subjects: 10

Group type: COMPARATOR
Intervention: Palatal infiltration with 2% plain lidocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palatal infiltration with 2% lidocaine plus 1:80,000 epinephrine
Number of subjects: 10
Study: 9350242

Group type: EXPERIMENTAL
Intervention: MMC + HCFU (intravenous MMC 6 mg/m2 on the day of operation followed by oral HCFU for 12 months from 2 weeks after operation)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: MMC + HCFU
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Operation only (Group Y)
Number of subjects: 1606
Study: 8478958

Group type: EXPERIMENTAL
Intervention: 30 g of ethanol (approximately two average drinks) per day for three menstrual cycles
Number of subjects: 34
Study: 3533551

Group type: EXPERIMENTAL
Intervention: Evening administration of controlled release theophylline (Uniphyllin)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Morning administration of controlled release theophylline (Uniphyllin)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (morning vs evening administration)
Number of subjects: 17
Study: 31829943

Group type: EXPERIMENTAL
Intervention: Stent optimisation group
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Non-optimisation group
Number of subjects: 1396
Study: 31482309

Group type: EXPERIMENTAL
Intervention: TTE + taurine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3MAOT + taurine
Number of subjects: 12

Group type: COMPARATOR
Intervention: TTE + placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3MAOT + placebo
Number of subjects: 12
Study: 27488187

Group type: EXPERIMENTAL
Intervention: Child Development Accounts (CDA) intervention, which included an Oklahoma 529 College Savings Plan account, financial incentives, and financial information.
Number of subjects: 2704

Group type: COMPARATOR
Intervention: Control group (no CDA intervention)
Number of subjects: 2704
Study: 26251065

Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy (CBT) and individual job support
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1193
Study: 23290982

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronate 5 mg
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2001
Study: 21303636

Group type: EXPERIMENTAL
Intervention: Differentiated SoloSTAR® pens (insulin glargine vs insulin glulisine)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Undifferentiated SoloSTAR® pens
Number of subjects: 400

Group type: COMPARATOR
Intervention: FlexPen® (insulin detemir vs insulin aspart)
Number of subjects: 400
Study: 19577022

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) 2 hours/day for 3 months
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sham (placebo) treatment 2 hours/day for 3 months
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF)
Number of subjects: 225
Study: 16455169

Group type: EXPERIMENTAL
Intervention: Third-generation hepatitis B vaccine containing PreS1 and PreS2 antigens in addition to the S antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hepatitis B vaccine
Number of subjects: 0
Study: 15523433

Group type: EXPERIMENTAL
Intervention: Floseal hemostatic sealant
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional suction cautery
Number of subjects: 70
Study: 11704163

Group type: EXPERIMENTAL
Intervention: 5 g of metronidazole gel intravaginally
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 224
Study: 9561954

Group type: EXPERIMENTAL
Intervention: CSTAR program services
Number of subjects: 280
Study: 7883389

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 24
Study: 3126085

Group type: EXPERIMENTAL
Intervention: Superselective intra-arterial chemotherapy with mitomycin C (SIAC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hepatic artery ligation (HAL) +/‐ 5-fluorouracil (5-FU)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Chemotherapy toxicity after SIAC
Number of subjects: 47
Study: 31803986

Group type: EXPERIMENTAL
Intervention: Volunteers often to always informed about the organisation of patient care
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers feeling their opinion is taken into account
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers reporting decision rights
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers reporting autonomy
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers reporting lack of information exchange
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers reporting ambiguity regarding tasks
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Volunteers expressing desire for stronger involvement in care organisation
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Collaboration with professionals
Number of subjects: 2273

Group type: EXPERIMENTAL
Intervention: Collaboration with nurses
Number of subjects: 2273
Study: 29898670

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (intervention group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 25748415

Group type: EXPERIMENTAL
Intervention: Amoxicillin (two 500 mg tablets three times a day for 7 days)
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 2061
Study: 24160442

Group type: EXPERIMENTAL
Intervention: Systematic CVD risk reduction package including healthy lifestyle counseling, prescription of a combination of drugs (antihypertensives, aspirin, and statin), and adherence support.
Number of subjects: 31708

Group type: COMPARATOR
Intervention: Usual care for hypertension and diabetes management at individual clinicians' discretion.
Number of subjects: 31708

Group type: EXPERIMENTAL
Intervention: Systematic CVD risk reduction package
Number of subjects: 31708
Study: 22024856

Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline/gentamicin irrigation
Number of subjects: 40
Study: 18297400

Group type: EXPERIMENTAL
Intervention: Supportive services plus school-based mentoring (SBM)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Supportive services alone
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Supportive services plus SBM
Number of subjects: 516
Study: 17133048

Group type: EXPERIMENTAL
Intervention: Interrupted suturing technique (IR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Single running sutures (SR)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combined interrupted and running sutures (CIR)
Number of subjects: 103
Study: 14519176

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 11083312

Group type: EXPERIMENTAL
Intervention: Acute geriatrics‐based ward (AGW)
Number of subjects: 413

Group type: COMPARATOR
Intervention: General medical wards (MWs)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Both AGW and MW
Number of subjects: 413
Study: 8884548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2716
Study: 1303480

Group type: EXPERIMENTAL
Intervention: Propofol 2.04 mg/kg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Methohexitone 1.05 mg/kg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study: 6099757

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Cefotaxime (multiple doses)
Number of subjects: 355
Study: 31205183

Group type: EXPERIMENTAL
Intervention: Microsurgical subtotal discectomy (MSD)
Number of subjects: 158
Study: 29381803

Group type: EXPERIMENTAL
Intervention: Capsinoids (12 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold exposure (∼14.5°C for ≤2 hours)
Number of subjects: 20
Study: 27055970

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids plus vitamin E
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23962492

Group type: EXPERIMENTAL
Intervention: Primary School Action for Better Health (PSABH) programme to train teachers to deliver HIV-prevention education
Number of subjects: 26461
Study: 19320914

Group type: EXPERIMENTAL
Intervention: Leaflet group
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Videotape group
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 287
Study: 15777554

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Number of subjects: 1089
Study: 11170979

Group type: EXPERIMENTAL
Intervention: Potent antiretroviral therapy including ritonavir and saquinavir
Number of subjects: 41
Study: 9929861

Group type: EXPERIMENTAL
Intervention: LactaPrev System (LPS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Disposable breast pads
Number of subjects: 55